找到相关结果： 922

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs

Press Release London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f

公告及新闻稿, 集团 | 2016-03-04

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-03-02

和黄医药启动索凡替尼以甲状腺癌为适应症的II期临床研究

1 个附件

2016年3月2日：和黄医药今日宣布正式启动索凡替尼（HMPL-012）以局部晚期或放射性碘难治性转移分化的甲状腺癌（DTC）或甲状腺髓样癌（MTC）为适应症在中国开展的一项开放式II期临床研究，

下载新闻稿 (PDF)

公告及新闻稿, 集团 | 2016-03-01

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

公告及新闻稿, 集团 | 2016-03-01

Final Results for the year ended 31 December 2015

Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III

公告及新闻稿, 集团 | 2016-02-11

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

公告及新闻稿, 监管通知 | 2016-01-29

Notice of Announcement of 2015 Final Results

London: Friday, 29 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) will be announcing its final results for the year ended 31 December 2015 on Tuesday, 1 March 2016. An analyst presentation will be held at 9:00 am on the

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-01-15

和黄医药在澳大利亚启动HMPL-523以血液肿瘤为适应症的I期临床试验

1 个附件

2016年1月15日：和黄医药今日宣布在澳大利亚启动HMPL-523以恶性血液肿瘤为适应症的I期临床试验。HMPL-523是针对B细胞受体信号通路中的酪氨酸激酶Syk的新型高选择性小分子抑制剂。此次研究的

下载新闻稿 (PDF)

公告及新闻稿, 监管通知 | 2015-12-29

Blocklisting Six Monthly Return

London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutc

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2015-12-18

和黄医药启动索凡替尼以神经内分泌瘤为适应症的III期临床研究

1 个附件

2015年12月18日：和黄医药今日宣布正式启动索凡替尼（HMPL-012）以非胰腺神经内分泌瘤为适应症的中国III期临床研究（SANET-ep）。此次研究的受试者均为非胰腺神经内分泌瘤患者，包括原发于�

下载新闻稿 (PDF)

公告及新闻稿, 其他业务, 新闻稿 | 2015-12-09

US$105 million Shanghai land compensation agreement

Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-12-08

和黄医药启动呋喹替尼以非小细胞肺癌为适应症的III期临床试验

1 个附件

2015年12月8日: 和黄医药今日宣布呋喹替尼（HMPL-013）以晚期非鳞状非小细胞肺癌为适应症的中国III期临床试验（FALUCA）正式启动。呋喹替尼是一种新型高选择性抑制血管细胞内皮生长因子受�

查看公告 (PDF)

公告及新闻稿, 集团 | 2015-11-13

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing

The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM

公告及新闻稿, 监管通知 | 2015-11-10

Results of Extraordinary General Meeting

London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were

公告及新闻稿, 监管通知 | 2015-11-09

Director's Share Dealing

London: Monday, 9 November 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby makes the following amendments to the "Director's Share Dealing" announcement released on 20 October 2015 subsequent to the notification received from Mr

演示文稿, 科学出版物 | 2015-11-07

EORTC 2015: Synergistic effect of c-Met inhibitor Savolitinib in combination with a VEGFR inhibitor Fruquintinib in clear cell renal cell carcinoma xenograft models

Abstract (please download the poster for full details): Authors: Yongxin Ren, Shiming Fan, Yunxin Chen, Renxiang Tang, Wei Zhang, Jianxing Tang, Linfang Wang, Dongxia Shi, Hongbo Chen, Min Cheng, Weiguo Qing, Weiguo Su Renal cell carcinoma (RCC

演示文稿, 科学出版物 | 2015-11-06

EORTC 2015: First-in-human phase I study of selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors

Abstract (download poster for full details): Authors: Jian-Ming Xu, Lin Shen, Yan Wang, Yu-ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Hua Ye, Su Weiguo Background: Sulfatinib is a highly selective oral small molecule inhi

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-11-06

和黄医药启动索凡替尼在美国的临床试验

1 个附件

2015年11月6日：和黄医药今日宣布启动索凡替尼（HMPL-012）在美国的I期临床试验。该药的美国新药临床研究申请于今年递交并通过，2015年11月4日首位受试者接受给药治疗。此外，和黄医药将�

查看公告 (PDF)

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2015-10-30

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa

公告及新闻稿, 监管通知 | 2015-10-30

Total Voting Rights

London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-10-30

和黄医药宣布新型Syk抑制剂HMPL-523治疗免疫疾病的I期临床试验取得成功

1 个附件

2015年10月30日: 和黄医药（上海）有限公司（简称 “和黄医药” ）今日宣布成功完成HMPL‑523的I期临床试验。HMPL-523是针对B细胞受体信号通路中的酪氨酸激酶Syk的新型高选择性小分子抑制剂

查看公告 (PDF)

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-10-23

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment

London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt

公告及新闻稿, 监管通知 | 2015-10-20

Director's Share Dealing

London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has: purchased jointly with his spouse 4,512 ordi

公告及新闻稿, 监管通知 | 2015-10-19

Awards under Long Term Incentive Plan

London: Monday, 19 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that the Remuneration Committee of Chi-Med today granted conditional awards (the “LTIP Awards”) under the Long Term Incentive Plan (the “LTIP

公告及新闻稿, 新闻稿, 集团 | 2015-10-16

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing

Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti

公告及新闻稿, 集团 | 2015-10-16

Shareholders' Circular and Notice of Extraordinary General Meeting

London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U

公告及新闻稿, 集团 | 2015-10-16

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2015-10-13

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma

Press Release London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha

公告及新闻稿, 监管通知 | 2015-10-12

Holding(s) in Company

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or t

公告及新闻稿, 集团 | 2015-10-08

Winner of International Company of the Year 2015, AIM

At the 2015 AIM Awards, Chi-Med was awarded the title of International Company of the Year. The AIM Awards look at how companies and individuals harness AIM to power their growth and fulfil their strategy. The AIM Awards scrutinises recent joiners

演示文稿, 科学出版物 | 2015-09-27

ESMO 2015: Phase II trial of fruquintinib in metastatic colorectal cancer

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-09-14

和黄医药将在2015欧洲癌症大会公布呋喹替尼治疗结直肠癌的II期临床研究结果

1 个附件

2015年9月14日：和黄医药今日宣布将在2015年9月25日至29日于奥地利维也纳举行的欧洲癌症大会上公布呋喹替尼治疗转移性结直肠癌临床II期概念验证性试验的详细研究结果。呋喹替尼是一种�

查看公告 (PDF)

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-09-02

呋喹替尼第二个概念验证性临床研究达到主要终点

1 个附件

2015年9月2日: 和黄医药今日宣布呋喹替尼以晚期非鳞状非小细胞肺癌（NSCLC）为适应症的第二个概念验证性（POC）临床研究成功达到主要终点。研究结果显示该试验成功地达到了无进展生存期

查看公告 (PDF)

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-08-19

和黄医药与杨森制药终止HMPL-507项目相关的合作协议

1 个附件

2015年8月19日星期三：和黄医药今日宣布收到杨森制药(Janssen Pharmaceutical, Inc.)关于终止HMPL-507项目的合作研发协议的决定。和黄医药与杨森制药于2008年开始战略合作，并于2010年修订了合作协

查看公告 (PDF)

公告及新闻稿, 集团 | 2015-07-28

Interim Results for the Six Months Ended 30 June 2015

For the complete release, please download the PDF. --- Drug R&D Division - our Innovation Platform: enrolling 17 clinical trials (H1 2014: 10), with 24 targeted by year-end. China Healthcare and Consumer Products Divisions - our Commercial

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-07-23

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med

London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui

公告及新闻稿, 其他业务 | 2015-07-17

20-year invention patent granted on Chi-Med's best selling prescription drug

London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven

公告及新闻稿, 监管通知 | 2015-07-06

Notice of Announcement of 2015 Interim Results

London: Monday, 6 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) will be announcing its interim results for the six months ended 30 June 2015 on Tuesday, 28 July 2015. An analyst presentation will be held at 9:00 am on the same d

公告及新闻稿, 监管通知 | 2015-06-29

Blocklisting Six Monthly Return

London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM)announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-06-01

和黄医药在2015年度ASCO大会上公布沃利替尼 (AZD6094) Ib期肺癌临床数据

2015年6月1日: 和黄医药今日宣布，其合作伙伴阿斯利康公布了由和黄医药自主研发的c-Met抑制剂沃利替尼（AZD6094）与阿斯利康的候选药物AZD9291联合用药治疗非小细胞肺癌的Ib期临床试验的初�

公告及新闻稿, 肿瘤学 / 免疫学 | 2015-05-13

呋喹替尼首个概念验证性临床研究成功，和黄医药获得1800万美元里程碑付款

1 个附件

星期二，2015年5月12日：和黄中国医药科技有限公司今日宣布呋喹替尼以转移性结直肠癌为适应症的首个概念验证性（POC）临床研究达到预期终点，成功触发第一个里程碑，和黄医药将于2015�

查看公告 (PDF)

演示文稿, 科学出版物 | 2015-05-01

ASCO 2015: Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 (savolitinib) or selumetinib in EGFR-mutant lung cancer

Please see http://meetinglibrary.asco.org/content/109556 The associated abstract is available at http://meetinglibrary.asco.org/content/148945-156. Meeting: 2015 ASCO Annual Meeting Session: Developmental Therapeutics – Clinical Pharmacol

公告及新闻稿, 监管通知 | 2015-04-30

Total Voting Rights

London: Thursday, 30 April 2015: For information purposes, Chi-Med hereby notifies the market that as at 30 April 2015, the issued share capital of Chi-Med consisted of 53,299,964 ordinary shares of US$1.00 each, with each share carrying one right to

公告及新闻稿, 监管通知 | 2015-04-24

Results of Annual General Meeting

London: Friday, 24 April 2015: Chi-Med today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on 24 April 2015 were duly passed. Please download the PDF.

公告及新闻稿, 监管通知 | 2015-04-22

Director's Shareholding

London: Wednesday, 22 April 2015: Chi-Med received notification on 22 April 2015 that Mr Christopher Nash, Independent Non-executive Director, has purchased 1,388 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP18.00 pe

公告及新闻稿, 监管通知 | 2015-04-16

Director's Shareholding

London: Thursday, 16 April 2015: Chi-Med received notification on 16 April 2015 that Simon To, Executive Director and Chairman, has purchased 28,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP15.85 per share on 15

公告及新闻稿, 监管通知 | 2015-04-13

Director's Shareholding

London: Monday, 13 April 2015: Chi-Med received notification on 13 April 2015 that Simon To, Executive Director and Chairman, has purchased 25,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP14.215 per share on 10 A

公告及新闻稿, 监管通知 | 2015-04-08

Directors' Shareholding

London: Wednesday, 8 April 2015: Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase

公告及新闻稿, 监管通知 | 2015-04-01

Exercise of Options

London: Wednesday, 1 April 2015: Chi-Med announces that it has issued 64,038 ordinary shares of US$1.00 each (the "Shares") following the exercise of options by Mr Johnny Cheng, Executive Director and Chief Financial Officer of Chi-Med, at an exercis

公告及新闻稿, 监管通知 | 2015-04-01

Directors' Shareholding

London: Wednesday, 1 April 2015: Chi-Med received notifications on 1 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase Numbe

1 2 3 4 5 6 7 8 9 10 11 12 13

15 16 17 18 19